

=> b wpix

FILE 'WPIX' ENTERED AT 14:13:08 ON 24 JAN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED: 20 JAN 2006 <20060120/UP>
MOST RECENT DERWENT UPDATE: 200605 <200605/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
<http://scientific.thomson.com/support/products/dwpi/>

>>> FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS:
<http://scientific.thomson.com/support/products/dwpifv/>

>>> THE CPI AND EPI MANUAL CODES WILL BE REVISED FROM UPDATE 200601.
PLEASE CHECK:
<http://scientific.thomson.com/support/patents/dwpieref/reftools/classification>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
<http://scientific.thomson.com/media/scpdf/ipcrdwpf.pdf> <<<
'BIX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d all abex tech 198 tot

L98 ANSWER 1 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2004-068266 [07] WPIX

DNC C2004-028070

TI Eyesight enhancement and maintenance composition for preventing or
treating macular degeneration has vitamins, phytonutrient, and amino
acids.

DC B05

IN GORSEK, W F

PA (VITA-N) VITACOST.COM INC

CYC 1

PI US-----6649195 B1 20031118 (200407)* 3 A61K-035-78

ADT US-----6649195 B1 2002US-0192558 20020711

PRAI 2002US-0192558 20020711

IC ICM A61K-035-78

AB US 6649195 B UPAB: 20040128

NOVELTY - An eyesight enhancement and maintenance composition comprises
Vitamin A; Vitamin C; Vitamin E; ginkgo biloba;
docosahexanoic acid; alpha lipoic acid; bilberry
extract; selenium; L-taurine; lutein extract; lycopene; and grape seed
extract.

USE - For preventing or treating macular degeneration, cataracts,
glaucoma and other eye diseases.

ADVANTAGE - The invented composition exhibits a powerful protective
effect on the health of the eye.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B03-A; B03-F; B03-H; B04-A08; B04-A09;
B04-A10; B05-B02C; B07-B03; B10-A09A; B10-C04E; B14-N03

ABEX UPTX: 20040128

EXAMPLE - An eyesight enhancement and maintenance composition containing 5000 IU Vitamin A; 1 g Vitamin C; 500 IU Vitamin E; 700 IU; Vitamin D3; 50 mg thiamine; 10 mg riboflavin; 70 mg niacinamide; 50 mg pyridoxine hydrochloride; 800 mcg folic acid; 500 mcg vitamin B12; 300 mcg biotin; 50 mg pantothenic acid; 75 mcg iodine; 84 mg magnesium (from taurinate); 316 mg magnesium from oxide and magnesium ascorbate; 30 mg zinc; 200 mcg selenium; 2 mg copper; 75 mcg molybdenum; 160 mg bilberry extract; 10 mg lycopene; 20 mg lutein; 880 mcg zeaxanthin; 300 mg alpha lipoic acid; 600 mg N-acetyl-cysteine 600; 100 mg bioflavonoid (as rutin); 100 bioflavonoid as quercetin; 125 mg bioflavonoid (citrus bio complex standardized to 50%; 50 mg plant enzymes; 5 mg black pepper; 100 mg L-Glycine; 10 mg L-Glutathione; 900 mg L-Taurinate; 500 mg docosahexaenoic acid; 300 mg EPA (sic); 120 mg ginkgo biloba and 200 mg grape seed extract was prepared.

TECH UPTX: 20040128

TECHNOLOGY FOCUS - FOOD - Preferred Composition: The eyesight enhancement and maintenance composition comprises 10-15000 mg Vitamin C; 50-5000 IU Vitamin E; 10-2000 mg ginkgo biloba; 10-2000 mg docosahexanoic acid; 50-1000 mg alpha lipoic acid; 16-1600 mg bilberry extract; 50-600 mg selenium; 90-9000 mg L-aurine; 100 mcg-1000 mg lutein extract; 6-100 mg lycopene; and 10-2000 mg grape seed extract.

L98 ANSWER 2 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2003-209131 [20] WPIX

DNC C2003-053172

TI Multi-vitamin and mineral combination useful for treating asthma comprises vitamin B-complex, other B-vitamin, vitamin C, fat soluble vitamin, bioflavonoid, carotenoid, phytoestrogen, Coenzyme 10 and N-acetyl cysteine.

DC B05

IN BENJAMIN, S D; WEIL, A

PA (BENJ-I) BENJAMIN S D; (WEIL-I) WEIL A

CYC 1

PI US--2002155163 A1 20021024 (200320)* 7 A61K-033-00

ADT US--2002155163 A1 1999US-0472669 19991227

PRAI 1999US-0472669 19991227

IC ICM A61K-033-00

ICS A61K-031-355; A61K-031-385; A61K-031-51; A61K-031-525; A61K-031-59; A61K-031-69; A61K-031-695; A61K-031-95; A61K-033-24

AB US2002155163 A UPAB: 20030324

NOVELTY - A multi-vitamin, mineral combination comprises vitamin B-complex, other B-vitamins, vitamin C, fat soluble vitamin, bioflavonoid, carotenoid, phytoestrogen, Coenzyme 10 and N-acetyl cysteine.

DETAILED DESCRIPTION - A multi-vitamin and mineral combination (I) comprises: thiamin (a) (50-100 mg), riboflavin (b) (45-55 mg), niacin (c) (50-100 mg), vitamin B6 (d) (50-100 mg), folate (e) (400-800 micro g), vitamin B12 (f) (80-120 micro g), biotin (g) (80-220 micro g), pantothenic acid (h) (40-60 mg), choline (i) (40-60 mg), inositol (j) (40-60 mg), para-amino benzoic acid (k) (40-60 mg), vitamin C (l) (100-500 mg), calcium (m) (240-600 mg), magnesium (n) (120-275 mg), iodine (o) (120-180 micro g), selenium (p) (160-240 micro g), manganese (q) (0.8-1.2 mg), chromium (r) (200-800 micro g), molybdenum (s) (60-90 micro g), boron (t) (5-10 mg), zinc (u) (4.5-33 mg), potassium (v) (0.8-1.2 mg), silicon (w) (1.6-2.4 mg), sulfur (x) (4-6 mg), vanadium (y) (8-12 mg), citrus bioflavonoid complex (z) (32-48 mg), hesperidin complex (aa) (3.2-4.8 mg), rutin (bb) (32-48 mg), vitamin A (cc) (15000-25000 IU), vitamin D (dd) (320-480 IU), vitamin E (ee) (400-880 IU), lycopene (ff) (4-6 mg), lutein (gg) (4.8-7.2 mg), Coenzyme Q10 (hh) (15-60 mg) and N-acetyl cysteine (ii) (540-660 mg).

An INDEPENDENT CLAIM is also included for a multi-vitamin and mineral combination (II) comprising (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) (540-660 mg), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w), (x), (y), (z), (aa), (bb), (cc), (dd), (ee), (ff), (gg), (hh)

and alpha-lipoic acid (ii) (90-100 mg).

ACTIVITY - Antiasthmatic; Antidiabetic.

MECHANISM OF ACTION - None given.

USE - For supplementing nutritional intake of humans with asthma and diabetes; in the adjunct care of asthma and/or diabetes (claimed).

ADVANTAGE - The formulation is high-potency that minimizes the number of dosages needed for optimal nutritional supplementation. The formulation reduces the risk of vitamin and mineral overdosing and toxicity.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B03-A; B03-D; B03-E; B03-F; B03-G; B03-H
; B03-L; B04-B01C; B04-C02A1; B04-N04; B05-A01A; B05-A01B; B05-A03A;
B05-B01B; B05-B01D; B05-B02C; B05-C07; B06-A01; B10-A07; B10-A22;
B10-B02D; B10-C04; B10-E04C; B14-K01A; B14-S04

ABEX UPTX: 20030324

ADMINISTRATION - The formulation is administered orally (claimed). No dosage given.

TECH UPTX: 20030324

TECHNOLOGY FOCUS - BIOLOGY - Preferred Composition: In (I), the components (a)-(bb) are in a first formulation. The components (cc)-(hh) are combined in a second formulation and the N-acetyl cysteine is in a third formulation. In (II), the components (a)-(i) and (k)-(bb) and (j) (40-60 mg) are combined in a first formulation. The components (cc)-(hh) are combined in a second formulation. The alpha-lipoic acid and (j) (500-600 mg) are combined in a third formulation.

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Formulation: The first and the third formulations of multi-vitamin and mineral combinations (I) and (II) further comprise microcrystalline cellulose, stearic acid and magnesium stearate. The second formulation of (I) and (II) further comprises soybean oil, gelatin, water, glycerin, beeswax and caramel. In (I) and (II) the vitamin C is incorporated as Ester C. The first and the third formulations are administered orally in the form of tablet. The second formulation is administered orally in the form of soft gel. Preferred Components: The selenium is yeast-bound. The sulfur is incorporated as methylsulfonylmethane.

L98 ANSWER 3 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2002-415383 [44] WPIX

DNN N2002-326759 DNC C2002-117233

TI Composition useful in the treatment of obesity comprises at least one micronutrient and target absorbent compound.

DC B04 D13 J04 S03

IN BUCHANAN-BAILLIE-HAMILTON, P F; PECK, J C

PA (BUCH-I) BUCHANAN-BAILLIE-HAMILTON P F

CYC 96

PI WO---200212882 A2 20020214 (200244)* EN 86 G01N-033-487

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ

NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK

DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR

KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU

SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU---200176537 A 20020218 (200244) G01N-033-487

GB-----2370504 A 20020703 (200251) A61K-049-00

ADT WO---200212882 A2 2001WO-GB003554 20010807; AU---200176537 A

2001AU-0076537 20010807; GB-----2370504 A 2001GB-0017052 20010712

FDT AU---200176537 A Based on WO---200212882

PRAI 2001GB-0017052 20010712; 2000GB-0019327 20000808

IC ICM A61K-049-00; G01N-033-487

ICS A61P-003-04

AB WO 200212882 A UPAB: 20020711

NOVELTY - A composition comprises at least one active compound e.g. micronutrient or target compound absorbent.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the

following: 1) a method for comparing the relative inhibitory effects of several of target compounds (A1)/items on the ability of a test subject (A2)/(A2) exposed to the items to control their weight involving performing the method for each (A1)/item, and comparing the inhibitory effects of each (A1)/item; 2) a method for labeling and/or certifying an item according to its inhibitory effect on the ability of (A2) exposed to the item to control their weight involving performing the method for the item, and labeling and/or certifying the item based on a pre-determined scale according to their inhibitory effect; 3) a method of diagnosis and/or prognosis of a weight-control-related disorder or disease in (A2) involving performing a method and correlating the results obtained from the method with the disease state of the subject; 4) determining a test subject's progress in altering the extent to which their ability to control their weight has been inhibited involving performing the method at intervals, and comparing the results obtained from the method to establish the progress made; 5) production of a tailored advice plan for (A2) involving performing a method and providing a plan in accordance with the results obtained from the method. The plan provides a system for improving or maintaining the ability of (A2) to control their weight; 6) determining the extent of the inhibitory effect of (A1) on the ability of (A2) into whom (A1) is introduced to control their weight involving (i) determining the degree or severity by which (A1) affects each of several weight controlling systems (HICS) present in (A2); (ii) determining the persistence of (A1) in (A2); (iii) calculating the inhibitory effect as a function of values of (i) and (ii); 7) Use of the composition in the preparation of a medicament for the treatment of obesity; 8) production of a database of the inhibitory effects of several (A1)/items on the ability of (A2)/(A2) exposed to the items to control their weight involving performing the method for each (A1)/items, and combining the results into a database; 9) computer system for use in the performance of a method or displaying the output of the method, or displaying or accessing the database, comprising (a) a standard electronic computer circuit containing at least a random access memory, a read only memory, a processor; (b) a keyboard comprising several standard keyboard buttons; and (c) a display; 11) production of a labeled and/or certified item, involving providing the item to be labeled and/or certified, and performing the method on the item; 12) a database produced by the method; 13) a data carrier comprising the database; 14) determining the inhibitory effect of an item on the ability of (A2) exposed to the item to control their weight involving: a) optionally determining the amount of each of several (A1) in the item having an inhibitory effect on the ability of (A2) to control their weight; and 15) a system for improving or maintaining the ability of (A2) to control their weight including (a) a commodity provider, which provides commodities for (A2), (b) a certifier which certifies each commodity according to its inhibitory effect on the ability of (A2) exposed to the item to control their weight such that the subject can select each commodity to its certification. The certifier optionally uses an analyzer for determining the presence of (A1) in each commodity and a database of the inhibitory effect of (A1) present in the commodity on the ability of (A2) to control their weight.

ACTIVITY - Anorectic; Cardiant; Antiasthmatic; Antiallergic; Cytostatic; Dermatological; Immunosuppressive.

MECHANISM OF ACTION - Inhibitor.

USE - For cosmetic improvement of the subject, which does not suffer from obesity; for treatment of the subject suffering from obesity; for use in a method for treatment of obesity; for controlling the weight of the subject; in the preparation of the medicament for the treatment of obesity (all claimed); for the control and treatment of various conditions associated with obesity e.g. immune dysfunction, autoimmunity, cardiovascular disorder, pulmonary disorder (e.g. asthma), allergies, cancer, mood changes, neurological illness, changes in libido, hormonal disorders, reproductive dysfunction, congenital abnormalities, metabolic disorder (e.g. glucose dysregulation), muscular skeletal disorder, renal and genitourinary disorder and skin disorder.

ADVANTAGE - The composition achieves significantly more effective and long lasting weight reduction without the use of drugs which interferes

with the body's natural metabolism, by means of effectively restoring the body's own natural slimming system in a substantially natural manner.

Dwg.0/9

FS CPI EPI

FA AB; DCN

MC CPI: B03-L; B04-A10; B06-D01; B07-D08; B10-B02; B10-C04E; B10-E04B;
B14-D01; B14-E12; B14-F02B; B14-G01; B14-G02; B14-H01; B14-J01A4;
B14-J01B3; B14-K01; B14-K01A; B14-N01; B14-N12; B14-N17; B14-S04;
D03-H01T; J04-B01

EPI: S03-E14H

ABEX UPTX: 20020711

ADMINISTRATION - The composition is administered orally to or by the subject as discrete units as capsule, cachet, tablet lozenge, as powder or granule, solution or suspension in an aqueous or non-aqueous liquid such as a syrup, an elixir, an emulsion or a draught (claimed). The composition can also be administered topically, rectally, parenterally.

EXAMPLE - A female adult was maintained on a chemical calorie controlled diet for 3 months. A chemical calorie absorbent formulation (comprising 4 capsules containing pectin (300 mg each) and 4 capsules containing psyllium (500 mg each) to be taken with a minimum of water (400 ml), 4 capsules containing activated charcoal (500 mg each), 1 teaspoon (5 g) of bentonite clay mixed up with (200 ml) fluid (fruit juice)) was taken twice daily at least 20 minutes before breakfasting and after dinner at night. A micronutrient formulation (comprising components Vitamin

A (2,667 IU), beta-carotene (3,333 IU), Vitamin B1 (32 mg), Vitamin B2 (25 mg), Vitamin B3 (100 mg), Vitamin B5 (60 mg), Vitamin B6 (30 mg), Vitamin B12 (100 mg), Vitamin C (260 mg), Vitamin D (400 IU), Vitamin E (100 IU), folic acid (400 mcg), calcium (120 mg), zinc (15 mg), magnesium (17 mg), iron (7 mg), PABA (25 mg), choline bitartrate (60 mg), inositol (25 mg), silica (25 mg), boron (20 mg), phytase enzyme (5 mg), lutein (5 mg), manganese ascorbate (2.5 mg), chromium (200 mcg), molybdenum ascorbate (500 mcg), biotin (400 mcg), L-selenomethionine (200 mcg), iodine (150 mcg), bilberry extract (450 mcg) and a dietary supplement (comprising (mg) methionine (250), taurine (200), cysteine (500), tyrosine (500), L-5 hydroxytryptophan (100), glutathione (300), choline (250), silymarin extract (milk thistle) (100), inositol (100), sodium sulfate (100), lipase (50), alpha-lipoic acid (10), green tea extract (5), biotin (50 mcg), linseed oil (10), sunflower oil (2) (except potassium bicarbonate (3.36), magnesium carbonate (0.40), sodium bicarbonate (2.24)) were taken twice a day immediately before or after both meals of breakfast and dinner. A chemical calorie controlled dietary program from each substance was then determined by multiplying the concentration present by the respective chemical calorie rating and finally the loading for all the xenobiotic substances were added together. Body weight and size measurements were recorded on a weekly basis and the following changes obtained at 30 days intervals over this period. The results were as follows: on day 0, weight = 63 kg; chest = 90 cm; waist = 76 cm; hips = 91 cm; % body fat = 25.6% and after 90 days, weight = 58 kg; chest = 85.5 cm; waist = 66.5 cm; hips = 80 cm and % body weight = 17%.

TECH UPTX: 20020711

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Composition: The composition comprises micronutrients selected from methionine, glutathione, tyrosine, tryptophan or L-5 hydroxytryptophan. The composition further comprises at least one micro-nutrient selected from vitamin, mineral or fatty acid (preferably vitamin A, B1, B2, B6, magnesium, zinc; vitamin C, E, vitamin B3, B12, magnesium, zinc; iron or OMEGA-3-acid; coenzyme Q10, vitamin B5, iodine, choline, folic acid, biotin, betaine, inositol, vitamin D, lipoic acid, phosphatidyl choline, calcium, organic sulfur, copper, chromium, selenium, manganese, vanadium, molybdenum, boron, PABA (para-aminobenzoic acid), vitamin K or silicon). The composition further comprises at least one amino acid (I), essential fatty acids (II), phytonutrients (III), herbal detoxification remedies (IV), hormone balancing herbs, alkalizing substances or enzymes (V). (I) is isoleucine,

leucine, valine, lysine, phenylalanine, threonine, ethanolamine, glycine, serine, glutamine, glutamic acid, aspartic acid, arginine, histidine, alpha-ketoglutaric acid, alanine, asparagine, proline, carnitine, butyric acid or butyrate. (II) is an OMEGA-6 essential fatty acid. (I) or (II) is anthocyanidins, cysteine, or taurine. (III) is bioflavonoid, curcumin, catechin, lycopene, lutein, zeaxanthin, allium compound, capsaicin, coumarin, chlorophyll, ellagic acid, sulphoraphane, isothiocyanate, anthocyanin, proanthocyanin, phenolic acid, quercetin, monoterpene, limonoid, terpenene, indole; allyl sulfide, carotenoid or saponin. The target compound is ion exchange resin, mineral oil, chelating agent, squalene or squalane. The absorbent is present in at least two discrete dosage units in the composition of matter. The composition is a dietary supplement. The composition includes an alkalization supplement to adjust the pH balance in the body of (A2). (A1) is a xenobiotic chemical selected organic solvent (preferably carbamate, phthalate, chlorinated hydrocarbon solvent, aromatic hydrocarbons solvent, dioxin, aliphatic, or alicyclic solvent). Preferred Compound: (A1) is PCBs (2,4,5,2',3',6'-hexa; 2,4,5,2',4',6'-hexa; 2,4,5,2',3',6'-hexa; 2,3,4,5,2',4',5'-hepta; 2,3,4,6,2',3',4'-hepta; 2,3,4,5,3',4',5'-hepta; 2,3,5,6,3',4',5'-hepta); PBBs (2,4,5,3',4'-penta; 2,4,5,2',4',5'-hexa; 2,3,4,2',4',5'-hexa; 2,4,5,3',4',5'-hexa; 2,3,5,2',4',5',6'-hepta); organochlorine Pesticides (DDT; DDE; HCB; Oxychlorane; trans-Nonachlor; beta-BHC (lindane); Heptachlor epoxide; (Dieldrin); heavy metals (lead; cadmium). (A1) is one to which (A2) may be exposed through ingestion or other uptake from the environment or its metabolite. A1 is xenobiotic chemical selected from polychlorinated biphenyl or polybrominated biphenyl. Preferred Dosage: The dosage for any of the following components present in the composition is within the following ranges of preferred minimum dose (A)/desirable minimum dose (B)/preferred upper limit (C): Micronutrient vitamin A = 3,000/10,000/25,000 IU; vitamin B1 = 10/50/500 mg; vitamin B2 = 10/50/300 mg; Vitamin B3 = 20/50/400 mg; vitamin B5 = 20/50/1,000 mg; vitamin B6 = 20/100/500 mg; vitamin B12 = 20/100/1,000 mcg; Folic acid = 200/400/1,000 mcg; Choline = 100/300/1,000 mg; vitamin C = 500/3,000/20,000 mg; vitamin E = 100/400/1,400 IU; co-enzyme Q10 = 20/40/1,000 mg; magnesium = 200/400/2,000 mg; zinc = 10/20/200 mg; iron = 5/20/200 mg; non-citrus anthocyanidin complex (bilberry extract) = 20/25/1000 mg; tryptophan or L-5 = 50/200/4000 mg; hydroxytryptophan = 50/100/300 mg; tyrosine = 200/500/3000 mg; methionine = 100/500/3000 mg; cysteine = 100/500/4000 mg; taurine = 100/300/4000 mg; glutathione = 150/500/4000 mg; OMEGA-3 fatty acids (from linseed oil) = 4/20/150 g. Absorbent (A/B/C) activated charcoal = 500 mg/2 g/20 g; soluble fiber (e.g. pectin) = 1/3/30 g; clay (e.g. bentonite) = 1/5/30 g. The components are present at the desirable minimum dose, or a dosage of about 100 - 600 (preferably 100 - 300, especially 200)% of the desirable minimum dose. The composition comprises the following dosage unit preparations A-F: Preparation A: Component vitamin A = 2,667 IU; beta-carotene = 3,333 IU; vitamin B1 = 32 mg; vitamin B2 = 25 mg; vitamin B3 = 100 mg; vitamin B5 = 60 mg; vitamin B6 = 30 mg; vitamin B12 = 100 mcg; Vitamin C = 260 mg; vitamin D = 400 IU; vitamin E = 100 IU; folic acid = 400 mcg; calcium = 120 mg; zinc = 15 mg; magnesium = 17 mg; iron = 7 mg; PABA = 25 mg; choline bitartrate = 60 mg; inositol = 25 mg; silica = 25 mg; boron = 20 mg; phytase enzyme = 5 mg; lutein = 5 mg; manganese ascorbate = 2.5 mg; chromium = 200 mcg; molybdenum ascorbate = 500 mcg; biotin = 400 mcg; L-selenomethionine = 200 mcg; iodine = 150 mcg; bilberry extract = 50 mg; Preparation B: component Vitamin C = 2000 mg; Preparation C: Component magnesium = 200 mg; Preparation D: Component co-enzyme Q10 = 30 mg; Preparation E: Component Vitamin E = 400 IU; Preparation F: Component Vitamin B6 = 20 mg. The composition comprises the following dosage unit preparations A-C in conjunction with alkalizing mineral mixtures. (A) Amino acid supplement tablet (mg): methionine = 250; taurine = 200; cysteine = 500; tyrosine = 500; L-5 hydroxytryptophan = 100; glutathione = 300. (B) Liver Support supplement tablet (mg): choline = 250; silymarin extract (Milk Thistle) = 100; inositol = 100; sodium sulfate = 100; lipase = 50; alpha lipoic acid = 10; green tea extract = 5; biotin = 50 mcg; (C) Essential fats (g) linseed oil = 10, sunflower oil = 2. Preferred Method: The determination for (A1)

made in steps (i) and/or (ii) is based on results obtained for a second compound containing same active moiety as (A1). The determination for (A2) in steps (i) and/or (ii) is based on results obtained for at least one representative member of population or sub-population to which (A2) belongs or is based on results obtained for a second subject which is different species to (A2). The method includes the step of weighting the results from the second subject in accordance with its physiological proximity to the first subject. The determination made in step (i) and/or (ii) is not contemporary with the calculation at (iii). The determination made in step (i) and/or (ii) is given a statistical measure of relevance based on the number of studies or trials used to support the determination. The statistical measure of relevance is obtained from a data quality index chart. The determination made in step (ii) is a longevity index, which is equal to the square root of the half-life of (A1) in the body of (A2) in hours. The persistence is obtained from a longevity indices conversion chart. The determination made in step (i) assessed for at least 2 or 3 of the following WCS: hormonal system; metabolism; muscular activity. At least one of the following WCS is assessed: noradrenaline, adrenaline, dopamine, serotonin, GABA, thermoregulation, brown fat metabolism, thyroid hormone, testosterone, oestrogen, progesterone, leutinizing hormone (LH) and follicle stimulating hormone (FSH), prolactin, cortisol, insulin, growth hormone and leptin, ATPase, carbohydrate metabolism, lipid metabolism, muscle tissue, protein synthesis, increased food intake, increased percentage of body fat, significant weight gain. The effect on each WCS is scored on a scale of 0 to 10. The determination made in step (i) is given weighting according to the significance of each WCS to the test subject's ability to control their weight. The total for each WCS determined at (i) is multiplied by the value determined at (ii) to provide the inhibitory effect of (A1). The inhibitory effect on an average weight (A2) is assessed per unit mass of (A1). The method for determining the inhibitory effect of the item involves: a2) determining the inhibitory effect of each (A1); a3) determining the degree to which exposure of (A2) to the item results in introduction into (A2) of each of several (A1) in the item, and a4) calculating the inhibitory effect of the item as a function of values of the above steps. Prior to performing the method for comparing the relative inhibitory effects of (A1), the item is categorized into categories based on the nature of (A1) which is present in each of the categories e.g. foodstuff, skin-care product, air sample, item of furniture, material for food packaging. Prior to step a1) the item is categorized into pre-determined elements based on the nature of (A1) present in each of the elements. The item is analyzed only for those (A1) which is present, based on historical analyses. The sensitivity with which the amount, of each of the several (A1) in the item, is determined is varied according to the inhibitory effect of (A1) whereby higher sensitivity is applied for more inhibitory (A1). The function in step a4) is given by the totality for each (A1) of the value determined at (a1) multiplied by the value determined at (a2) factored by the value determined at (a3) such as to provide the total inhibitory effect of the item. The method is for establishing that the inhibitory effect of the item does not exceed a minimum threshold. The method involves further step of categorizing or banding the items based on a pre-determined scale of inhibitory effect. The pre-determined scale is very low, low, medium, high, very high. The labeling and/or certifying is performed by incorporating information conveying the inhibitory effect into the item, its packaging, or ancillary materials associated with them. The inhibitory effect is determined for a representative item selected from a batch of items. The method for determining the extent to which (A2) has had their ability to control their weight inhibited, involves determining the amount of each of several of (A1) in (A2). The method further involves determining inhibitory effect of each (A1) present and calculating the inhibitory effect of the item as a function of values of (a1), (a2). The value for step (I) is determined from a biopsy sample removed from the test subject. The function in step (III) is given by the totality for each (A1) of the value determined at (a1) multiplied by the value determined at (a2).

TECHNOLOGY FOCUS - BIOLOGY - Preferred Components: (IV) is milk thistle,

burdock, red clover, fenugreek, echinacea, yellow dock, dandelion root, ginkgo biloba, blessed thistle, ginger root, sarsaparilla root, plantain leaf, saw palmetto berry, corn silk, fructo-oligosaccharide, garcinia cambogia, oligosaccharide, flax meal, elecampane root, schisandra berry, elderberry, clove, cat's claw, black walnut hull, goldenseal root, barley bran, wheat bran, tumeric, aloe vera, hibiscus, echinacea, fenugreek, dong quai, astragalus root, micro algae, melatonin, pinus maritima, kelp, slippery elm, sorrel, marshmallow root, fennel seed, barberry rootbark, senna, curacao, cascara sagrada, green tea, African bird pepper, cayenne and probiotics, licorice root, ginseng, isoflavone, genistein, chaste tree berry, triphala, black cohosh, wild yam, saw palmetto or damiana.

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Components: (V) is lipase, protease, amylase, phytase, trypsin, chymotrypsin, lactase, catalase, superoxidase dismutase or glutathione peroxidase.

TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Composition: The composition comprises at least one target compound absorbent selected from charcoal, locust bean gum, oat bran and/or oat gum, konjac mannan, pectin, guar gum, acacia gum, rice bran, clay optionally selected from bentonite, kaolin or Fuller's earth.

TECHNOLOGY FOCUS - POLYMERS - The target compound is soluble fiber optionally selected from psyllium, sucrose polyester, chitin or other polyglusam.

TECHNOLOGY FOCUS - AGRICULTURE - Preferred Components: (A1) is a xenobiotic chemical selected from pesticide, environmental pollutant or heavy metal (preferably A1 is a xenobiotic chemical selected from organochlorine insecticide or organophosphate insecticide).

TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred System: The system optionally further includes (c) an advisor which advises the individual on selection of each commodity according to its inhibitory effect on the ability of (A2) exposed to the item to control their weight. The advisor optionally uses an analyzer which determines the presence of (A1) in (A2); (d) a commodity provider, provides compositions for reducing the level of (A1) in (A2); (e) a certifier which certifies the composition according to their ability to reduce the level of (A1) in (A2).

TECHNOLOGY FOCUS - FOOD - Preferred Foodstuff: The item is foodstuff categorized into following elements e.g. integral packaging; non-ingestible portions or types of ingestible material. The inhibitory effect is declared for 100 g or 100 ml of the foodstuff and/or a typical portion of the foodstuff. The item is packaging for food, its inhibitory effect is assessed by comparing the inhibitory effect of the foodstuff packaged in the item with an equivalent unpackaged foodstuff.

L98 ANSWER 4 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 AN 2001-541515 [60] WPIX
 DNC C2001-161626
 TI Dietary supplement useful in promoting health of joints and joint tissues comprises mixture of niacinamide and/or niacin, and an antioxidant nutrient.
 DC B05
 IN BLAND, J S
 PA (META-N) METAGENICS INC; (BLAN-I) BLAND J S
 CYC 91
 PI WO---200156572 A1 20010809 (200160)* EN 20 A61K-031-44
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZW
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
 FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
 LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
 TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
 AU---200134782 A 20010814 (200173) A61K-031-44

US--2002025310 A1 20020228 (200220) A61K-038-43

ADT WO---200156572 A1 2001WO-US003497 20010202; AU---200134782 A
2001AU-0034782 20010202; US--2002025310 A1 Provisional 2000US-179885P
20000202, 2001US-0776579 20010202

FDT AU---200134782 A Based on WO---200156572

PRAI 2000US-179885P 20000202; 2001US-0776579 20010202

IC ICM A61K-031-44; A61K-038-43
ICS A61K-031-195; A61K-031-198; A61K-031-20; A61K-031-355; A61K-031-385;
A61K-031-445; A61K-033-32

AB WO 200156572 A UPAB: 20011018
NOVELTY - A dietary supplement comprises mixture of a) niacinamide and/or
niacin, and b) an antioxidant nutrient.
ACTIVITY - Osteopathic; antiarthritic.
No biological data given.
MECHANISM OF ACTION - Poly(ADP-ribose) synthetase inhibitor.
USE - For promoting health of joints and joint tissues (claimed) by
providing nutritional support.
ADVANTAGE - The supplement helps to medicate and improve patient
prognosis without the side effects associated with NSAIDs and COX-2
inhibitors. Also, it counteracts the depletion of ATP that occurs in the
inflammation process and inhibits the deleterious effects of oxygen free
radicals.
Dwg.0/1

FS CPI

FA AB; DCN

MC CPI: B03-A; B03-H; B04-L02; B05-A03A; B07-B03;
B07-D04C; B10-A06; B10-C04D; B14-C09; B14-D10; B14-N01; B14-S08

ABEX UPTX: 20011018
ADMINISTRATION - The supplement is administered orally about 5 - 75
(preferably 10 - 60, especially 20 - 30) mg/kg/day.

EXAMPLE - A dietary supplement comprised (%) a mixture of niacin (21.2),
niacinamide (23.2), N-acetylcysteine (7.3), alpha
lipoic acid (7.3), coenzyme Q10
(7.3), vitamin E (2), alpha-carotene (0.1), beta-
carotene (4), cryptoxanthin (14.3), lutein (4), lycopene (2),
zeaxanthin (0.2) and zinc amino acid chelate (7.1).

TECH UPTX: 20011018
TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: (b) is
N-acetylcysteine, alpha lipoic acid,
coenzyme Q10, vitamin E, carotenoids and/or zinc
(preferably N-acetylcysteine). (a) is preferably
niacinamide. The supplement further comprises diluents, binders,
lubricants, disintegrants, coloring agents and/or flavoring agents.
Preferred Composition: The supplement comprises (wt.%) (a) (10 - 90
(preferably 30 - 85, especially 50 - 80)) and (b) (10 - 90 (preferably 15
- 70, especially 20 - 50)).

L98 ANSWER 5 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2000-564617 [52] WPIX

DNC C2000-168136

TI Oral composition used to treat macular degeneration, cataracts, elevated
ocular pressure, diabetic retinopathy and glaucoma comprises carotenoids
such as lycopene and lutein.

DC B02

IN GORSEK, W F

PA (VITA-N) VITACOST INC

CYC 1

PI US-----6103756 A 20000815 (200052)* 4 A61K-031-355

ADT US-----6103756 A 1999US-0372055 19990811

PRAI 1999US-0372055 19990811

IC ICM A61K-031-355
ICS A61K-031-07

AB US 6103756 A UPAB: 20001018
NOVELTY - Oral composition comprises vitamins A, E and
C, magnesium, selenium, bilberry extract, L-taurine, lutein extract,

lycopene extract, alpha lipoic acid, quercetin, rutin and citrus bioflavonoids.

ACTIVITY - Ophthalmological; antidiabetic.

No activity data is given.

MECHANISM OF ACTION - None given.

USE - The composition is used for the prevention, stabilization, reversal and treatment of age-related macular degeneration, cataracts, elevated ocular pressure, diabetic retinopathy and glaucoma.

ADVANTAGE - The composition helps to protect and neutralize free radicals that may damage vision and stops eye parts from wearing out.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B03-A; B03-F; B03-H; B04-A08C2;

B04-A10; B05-A01B; B05-B02C; B06-A01; B07-B03; B10-A09B; B14-N03

ABEX UPTX: 20001018

ADMINISTRATION - Administration is oral.

TECH UPTX: 20001018

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred composition: The composition also comprises at least one of vitamin D3, thiamine, riboflavin, niacin, vitamin B6, folic acid, vitamin B12, biotin, pantothenic acid, calcium, iodine, zinc, copper, manganese, chromium, molybdenum, n-acetyl-cysteine, plant extracts, biopene, malic acids, L-glycine, L-glutathione and boron.

The composition comprises vitamin C (100-6000 mg), vitamin E (100-2000 IU), vitamin A (100-2000 IU), L-taurine (100-1000 mg), Se (50-600 mug), bilberry extract (40-1000 mg), lutein extract (6-100 mg), lycopene extract (6-100 mg), alpha lipoic acid (50-1000 mg), quercetin (10-1000 mg), rutin (10-1000 mg) and citrus bioflavonoids (10-1000 mg).

L98 ANSWER 6 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1999-619630 [53] WPIX

CR 1999-418245 [35]; 1999-526388 [44]; 2002-681921 [73]; 2003-074233 [07]

DNC C1999-180805

TI Oral daily dosage dietary supplement for improving health and alertness.

DC B05

IN RILEY, P A

PA (MEDI-N) MEDICAL DOCTORS RES INST INC

CYC 1

PI US-----5976568 A 19991102 (199953)* 18 A61K-009-48

ADT US-----5976568 A Provisional 1996US-012158P 19960223, 1997US-0803587 19970221

PRAI 1996US-012158P 19960223; 1997US-0803587 19970221

IC ICM A61K-009-48

AB US 5976568 A UPAB: 20030820

NOVELTY - Oral daily dosage dietary supplement for improving health and alertness contains vitamins, minerals, plant extracts and other additives.

DETAILED DESCRIPTION - Oral daily dosage dietary supplement for humans comprises vitamin B1 (0.7-15 mg), vitamin B2 (0.7-15 mg), vitamin B6 (2-100 mg), niacin (6-100 mg), folate (50-800 micro g), pantothenic acid (4-50 mg), vitamin B12 (0.5-40 micro g), biotin (5-300 micro g), calcium (100-1500 mg), magnesium (25-500 mg), iron (1-20 mg), zinc (5-30 mg), manganese (1-10 mg), selenium (10-200 micro g), chromium (10-300 micro g), copper (0-4 mg), coenzyme Q10 (5-300 mg), vitamin A (200-15,000 IU), beta-carotene (500-15,000 IU), alpha-carotene (50-2000 micro g), lycopene (50-10,000 micro g), lutein (50-5000 micro g), zeaxanthine (5-500 micro g), vitamin C (20-1000 mg), vitamin D (0-400 IU), vitamin E (5-2000 mg), grape seed extract (0-300 mg), green tea extract (0-500 mg), hawthorn berry extract (0-500 mg), L-carnitine (0-700 mg), alpha-lipoic acid (0-750 mg), taurine (15-1000 mg), quercetin (0-500 mg) and odorless garlic (0-500 mg).

An INDEPENDENT CLAIM is also included for a modular system for providing micronutrient supplementation to a human, comprising:

(a) a morning oral dosage composition comprising beta-

carotene (12500 IU), alpha-carotene (250 IU), lutein (400 micro g), lycopene (400 micro g), zeaxanthine (20 micro g), vitamin A (3000 IU), vitamin B1 (4-5 mg), vitamin B2 (5 mg), niacinamide (33 mg), pantothenic acid (15 mg), vitamin B6 (5-6 mg), biotin (150 micro g), folic acid (300 micro g), vitamin B12 (6 micro g), vitamin C (150 mg), vitamin D3 (300 IU), vitamin E (60-70 IU), calcium (200-225 mg), chromium (80 micro g), copper (0.5 mg), iron (8-12 mg), magnesium (100 mg), manganese (4 mg), selenium (25 micro g), zinc (10-50 mg) and odorless garlic (25 mg); and

(b) an evening oral dosage composition comprising beta-carotene (400 IU), alpha-carotene (100 IU), lutein (100 mu g), lycopene (100 micro g), zeaxanthine (5 micro g), vitamin A (2000 IU), vitamin B1 (2-3 mg), vitamin B2 (2 mg), niacinamide (7 mg), pantothenic acid (5 mg), vitamin B6 (2 mg), biotin (50 micro g), folic acid (100 micro g), vitamin B12 (3 micro g), vitamin C (100-150 mg), vitamin D3 (100 IU), vitamin E (30-40 IU), calcium (275-345 mg), chromium (20 micro g), copper (0.5 mg), iron (2-3 mg), magnesium (100 mg), manganese (1 mg), selenium (25 micro g), zinc (5-10 mg) and odorless garlic (25-50 mg);

ACTIVITY - None given.

MECHANISM OF ACTION - None given.

USE - To improve health and alertness.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B03-A; B03-B; B03-C; B03-D; B03-E; B03-F; B03-G; B03-H; B04-A09D; B04-A10B; B04-A10G; B04-L02; B05-A01B; B05-A03; B06-A01; B06-D09; B07-D04C; B10-A09B; B10-A22; B10-C04D; B14-E11

ABEX UPTX: 19991215

WIDER DISCLOSURE - The dietary supplement can also contain aspirin for prophylaxis of coronary heart disease.

L98 ANSWER 7 OF 7 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1999-526388 [44] WPIX

CR 1999-418245 [35]; 1999-619630 [53]; 2002-681921 [73]; 2003-074233 [07]

DNC C1999-154680

TI Administering micronutrients and acetylsalicylic acid to prevent nutritional deficiencies and reduce coronary heart disease.

DC B05

IN CHRISTAKIS, G; RILEY, P A

PA (MEDI-N) MEDICAL DOCTORS RES INST INC

CYC 1

PI US-----5948443 A 19990907 (199944)* 17 A61K-033-32

ADT US-----5948443 A Provisional 1996US-012158P 19960223, 1997US-0804494 19970221

PRAI 1996US-012158P 19960223; 1997US-0804494 19970221

IC ICM A61K-033-32

ICS A61K-031-62

AB US 5948443 A UPAB: 20030820

NOVELTY - Modular system of multivitamin and mineral supplementation is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a new method to provide micronutrient and acetylsalicylic acid supplementation to treat nutritional deficiencies and to reduce coronary heart disease in humans comprising the daily administration of a multivitamin/mineral formulation (A) and acetylsalicylic acid.

(A) comprises: Vitamin B1 (0.7-15 mg), vitamin B2 (0.7-15 mg), vitamin B6 (2-100 mg), niacin (6-100 mg), folate (50-800 micro g), pantothenic acid (4-50 mg), vitamin B12 (0.5-40 micro g), biotin (5-300 micro g), calcium (100-1500 mg), magnesium (25-500 mg), iron (1-20 mg), zinc (5-30 mg), manganese (1-10 mg), selenium (10-200 micro g), chromium (10-300 micro g), copper (0-4 mg), Coenzyme Q10 (5-300 mg), vitamin A (200-15000 IU), beta carotene (500-15000 IU), alpha-carotene (50-2000 micro g), lycopene (50-10000 micro g), lutein (50-5000 micro g), zeaxanthin (5-500

micro g), vitamin C (20-1000 mg), vitamin D (0-400 IU), vitamin E (5-2000 mg), grape seed extract (0-300 mg), green tea extract (0-500 mg), crataegus (0-500 mg), oxyacantha extract L-carnitine (0-700 mg), alpha - lipoic acid (0-750 mg), taurine (15-1000 mg), quercetin (0-500 mg) and garlic (0-500 mg).

ACTIVITY - Dietary vitamin supplement; cardiant; antidiabetic; hypotensive; antianemic; cytostatic; osteopathic; antilipemic; thrombolytic; anticoagulant.

A study in seven healthy volunteers compared changes in blood clotting times induced by the modular system (Modules 1 and 4) with the use of conventional multivitamins with acetylsalicylic acid (81 mg). In the two female non-smokers taking the conventional preparations, clotting time was increased from 5.5 to more than 15 minutes. In the three smokers and two non-smokers who took Modules 1 and 4, the clotting times changed from 4-7.5 minutes to 3- more than 15 minutes.

MECHANISM OF ACTION - Platelet deagglutinator; thrombus inhibitor; antioxidant.

Vitamin and antioxidant biochemical action. The combination of acetylsalicylic acid and an antioxidant prevents the oxidation of low density lipoproteins in the coronary artery walls.

USE - For the treatment of nutritional losses and deficiencies and to reduce the risk of coronary heart disease (claimed).

To treat or prevent micronutrient deficiency and reduce atherosclerotic-induced coronary heart disease, Syndrome X, diabetes, stress related disorders e.g. mucous colitis and hypertension, immunodeficiency, anemia, fatigue, osteoporosis, cancer, hyperlipidemia and thrombosis in humans. Separate formulations for men and women can be used.

ADVANTAGE - The appropriate formulation matched to specific physiological needs provides optimal results and avoids ingredients counteracting each other or impairing absorption of other ingredients. Platelet deagglutination and thrombus inhibition occur without prolonged blood clotting times and without the side effects of ulceration associated with a higher daily dose of acetylsalicylic acid.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B03-L; B04-A10; B04-L02; B05-A01B; B05-A03; B06-D09; B06-F03; B07-B03; B07-D04C; B10-A09B; B10-A21; B10-C03; B10-C04D; B14-F01B; B14-F02B; B14-F03; B14-F04; B14-F06; B14-F07; B14-G01; B14-H01; B14-K01E; B14-N01; B14-S04

ABEX UPTX: 19991026

ADMINISTRATION - The supplement is given orally on a daily basis. Module 1 has morning and evening dosage formulas.

Modules 1, 2, and 3 can be taken in any combination (preferably all together), and are compatible with the intake of acetylsalicylic acid.

Modules 4, 5, and 6 or 7 are recommended similarly.

TECH UPTX: 19991026

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition is a modular system of 7 formulations to be taken in combination. Module 1 is the basic formula, an antioxidant vitamin-mineral composition for daily use in morning and evening doses suitable for coadministration with acetylsalicylic acid. Module 2 is a stress formula, a multivitamin formulation with calcium, zinc and magnesium. Module 3 is formulated to combat Syndrome X, and is available in 2 strengths. Module 4 is acetylsalicylic acid (30, 55, 81 or 200 mg). Module 5 is Module 1 morning formulation and acetylsalicylic acid (20 mg). Module 6 is Module 1 morning formulation and acetylsalicylic acid (81 mg). Module 7 is a low dose version of Module 3 and acetylsalicylic acid (81 mg).

=> d all abex tech 188 tot

L88 ANSWER 1 OF 3 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2005-477953 [48] WPIX

DNC C2005-145576

noble jarrell 24/01/2006

TI Nutrient composition, useful for augmenting immune strength or physiological detoxification, comprises an optimal combination of vitamin antioxidant, mineral antioxidant and high potency antioxidants.

DC B05

IN KAISER, J D; KAISER, J

PA (KAIS-I) KAISER J D; (INTE-N) INTEGRATIVE HEALTH CONSULTING
INC

CYC 107

PI US--2005142124 A1 20050630 (200548)* 21 A61K-038-43 <--
WO--2005067972 A1 20050728 (200551)# EN A61K-045-00

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM
PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US
UZ VC VN YU ZA ZM ZW

AU--2003300167 A1 20050803 (200570)# A61K-045-00

ADT US--2005142124 A1 2003US-0750545 20031231; WO--2005067972 A1
2003WO-US41780 20031231; AU--2003300167 A1 2003AU-0300167 20031231,
2003WO-US41780 20031231

FDT AU--2003300167 A1 Based on WO--2005067972

PRAI 2003US-0750545 20031231; 2003WO-US41780
20031231; 2003AU-0300167 20031231

IC ICM A61K-038-43; A61K-045-00
ICS A61K-031-198; A61K-031-353; A61K-031-375; A61K-031-70;
A61K-038-00; A61K-038-05

AB US2005142124 A UPAB: 20050728
NOVELTY - Nutrient composition (I), for augmenting immune strength or physiological detoxification, comprises: an optimal combination (substantially pure) of at least one vitamin antioxidant (A), at least one mineral antioxidant (B) and a highly saturable amount of at least three high potency antioxidants (C).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) methods of stimulating immune system function and augmenting a therapeutic treatment of a disease comprising the administration of (I), one or more times a day, over a period of 5-7 weeks, where the immune system function is stimulated to result in an increase of CD4+ cells of at least about 15% compared to pre-administration levels; and

(2) methods of stimulating a physiological detoxification function of an individual and augmenting a therapeutic treatment of a disease comprising the administration of (I), one or more times a day over a period of about 5-7 weeks, where the physiological detoxification function is stimulated to result in a decrease of one or more free radical markers by about 20% compared to pre-administration levels.

ACTIVITY - Immunostimulant; Antidote; Immunomodulator; Cytostatic; Cardiant; Muscular-Gen.; Neuroprotective; Antiemetic; Vasotropic; Antimicrobial; Anti-HIV; Antiinflammatory; Dermatological; Immunosuppressive; Antiarthritic; Antirheumatic; Antiartherosclerotic; Nootropic; Antiparkinsonian; Hepatotropic; Virucide; Vulnerary.

MECHANISM OF ACTION - None given.

USE - (I) is useful to stimulate immune system function and to augment therapeutic treatment of diseases; and to stimulate physiological detoxification function of an individual and to augment therapeutic treatment of diseases, where the diseases are immune-mediated diseases, cancer, heart disease, chronic fatigue syndrome, neurodegenerative diseases, radiation poisoning, ischemic events or an infectious disease (particularly AIDS, multiple sclerosis, lupus, rheumatoid arthritis, scleroderma, coronary artery disease, atherosclerotic vessel disease, Madalung's disease, neoplastic conditions, solid tumor malignancies, non-solid malignancies, Alzheimer's disease, Parkinson's disease, neurodegenerative forms of dementia, infectious hepatitis, toxic hepatitis, drug-induced hepatitis, herpes or HIV) (claimed). The compositions are useful to promote healing process of physiological disorders/diseases. The ability of (I) to stimulate immune system function was tested using biological assays. The results indicated that the

patients taking (I) sustained a 64 cell rise in absolute CD4+ cell counts when compared to a 13 cell rise in patients taking the placebo.

ADVANTAGE - The immune system function is stimulated to result in an increase of CD4+ cells of at least about 15% (preferably about 40%) compared to pre-administration levels. The stimulation of the immune system function promotes longevity and physiological healing. The physiological detoxification function is stimulated to result in a decrease of one or more free radical markers by about 20% (preferably about 50%) compared to pre-administration levels. The compositions comprises (A), (B), (C), vitamins and minerals in a purity level of about 99% by total weight (all claimed). The composition enhances the efficacy of therapeutic treatments and provides desirable health benefits.

Dwg.0/3

FS CPI

FA AB; DCN

MC CPI: B03-A; B03-B; B03-C; B03-D; B03-E; B03-F;
B03-H; B04-B03A; B04-B03D; B04-L02; B05-A03A4; B05-B02C;
B06-A01; B06-F03; B07-B03; B10-A22; B10-B02D; B10-E04B; B14-A02B1;
B14-C03; B14-C09; B14-F01; B14-F02D; B14-F07; B14-G01; B14-G01B;
B14-H01; B14-J01A3; B14-J01A4; B14-J01B3; B14-M01; B14-N12; B14-S01

ABEX UPTX: 20050728

ADMINISTRATION - Administration of (I) is oral. Dosage of coenzyme Q10, glutathione and alpha lipoic acid is: 30-300 mg/70 kg/day, 100-600 mg/70 kg/day and 200 mg/70 kg/day respectively.

TECH UPTX: 20050728

TECHNOLOGY FOCUS - BIOLOGY - Preferred Method: The stimulation of a physiological detoxification function comprises: inhibiting mitochondrial DNA polymerase gamma; or increasing a liver detoxification function (particularly an increase in energy production, an increased ability to process toxins or a decrease in free radical build-up/markers). The method of augmenting of the therapeutic treatment comprises: stimulation of immune system function or reduction in cellular toxicity resulting from the therapeutic treatment (HIV medications (comprising reverse transcriptase inhibitors (a nucleoside inhibitor, a nucleotide inhibitor or a non-nucleoside inhibitor; particularly an HIV protease inhibitor)) or administration of stavudine or didanosine).

TECHNOLOGY FOCUS - FOOD - Preferred Composition: (I) preferably comprises an optimal combination (substantially pure) of at least three vitamin antioxidants, at least two mineral antioxidants and a highly saturable amount of at least three high potency antioxidants. The nutrient composition (III), for augmenting immune strength or physiological detoxification, comprises an optimal combination (substantially pure) of vitamin C, bioflavonoid complex, vitamin E, zinc, selenium, alpha lipoic acid, acetyl L-carnitine and N-acetylcysteine. Preferred Components: (C) are alpha lipoic acid, acetyl L-carnitine, N-acetyl-cysteine, co-enzyme Q10 or glutathione (preferably alpha lipoic acid, acetyl L-carnitine or N-acetyl-cysteine). (A) is vitamin C, bioflavonoid complex, vitamin E, vitamin B6 or betacarotene (preferably vitamin C, bioflavonoid complex or vitamin E). (B) is zinc or selenium. (I) further comprises one or more vitamins or minerals (preferably beta-carotene, vitamin A, vitamin B1, vitamin B2, niacinamide, calcium panthothenate, choline, inositol, folic acid, biotin, vitamin D3, vitamin B12, calcium, magnesium, iron, iodine, copper, manganese, potassium, chromium, molybdenum, boron, betaine or glutamic acid) in a purity level of about 99% by total weight. The two mineral antioxidants comprise zinc and selenium. (III) further comprises vitamin B6 and one or more vitamins or minerals. The components of (III) comprise a purity level of about 99% by total weight.

L88 ANSWER 2 OF 3 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2004-223719 [21] WPIX

DNC C2004-088159

TI Controlled release pharmaceutical formulation for administration of, e.g. bupropion to subject, comprises bupropion hydrochloride, uncrosslinked polymer, e.g. hydroxyethyl cellulose, and crosslinked insoluble polymer.

DC A11 A14 A25 A26 A96 B05 B07
 IN ODIDI, A; ODIDI, I
 PA (INTE-N) INTELLIPHARMACEUTICS CORP
 CYC 1
 PI US-----6652882 B1 20031125 (200421)* 5 A61K-009-10
 ADT US-----6652882 B1 Provisional 1997US-061121P 19971006, 1998US-0166365
 19981005
 PRAI 1997US-061121P 19971006; 1998US-0166365 19981005
 IC ICM A61K-009-10
 ICS A61K-009-16; A61K-009-22; A61K-047-38
 AB US 6652882 B UPAB: 20040326
 NOVELTY - A controlled release pharmaceutical formulation comprises bupropion hydrochloride, 20-25 weight% uncrosslinked polymer consisting of hydroxyethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, and/or hydroxypropylethyl cellulose; and 1-70 weight% crosslinked insoluble polymer.
 ACTIVITY - None given.
 MECHANISM OF ACTION - None given.
 USE - For administration of antidepressant drugs, e.g. bupropion, to a subject.
 ADVANTAGE - The inventive formulation is released over a period to provide improved availability of the drug, or is released either in continuous or pulsatile manner. It is simple in fabrication, permitting efficient and reproducible mass production by conventional technique. The stabilizing agent improves the stability of bupropion hydrochloride on storage of the formulation. The polymer content can be adjusted to give a desired rate of release for over 12, 24, and 48 hours.
 Dwg.0/0
 FS CPI
 FA AB; DCN
 MC CPI: A12-V01; B03-F; B04-C02A; B04-C03; B05-A01B; B05-A03A;
 B05-B02C; B10-B04B; B12-M05; B12-M10
 ABEX UPTX: 20040326
 ADMINISTRATION - The formulation can be administered orally at 150-400 mg/day.
 EXAMPLE - Bupropion hydrochloride (1-70 weight%) was blended with 1-60 weight% hydroethylcellulose polymer, and optionally lactose or microcrystalline cellulose and/or talc in a planetary or high shear mixer. The homogeneous blend was granulated with a granulating solution of Gelucire 44/14 in isopropyl alcohol in the mixer. The Gelucire 44/14 is 1-55 weight% dry ingredients. It was preferable to knead the wet mass for 1-3 minutes after wet granulation. The wet granules were dried in fluid bed dryer or tray dryer to a loss on drying of less than 5%. Size reduction of the dried granules was carried out in a cone mill such that granule size was less than 1400 microm. The milled granules were blended with a lubricant such as magnesium stearate in the V-blender. The lubricated granules were compressed into tablets and the resulting tablets had a hardness of greater than 5 Strong Cobb units and friability of less than 1%.
 TECH UPTX: 20040326
 TECHNOLOGY FOCUS - POLYMERS - Preferred Component: The crosslinked, insoluble polymer is an acrylic acid polymer. The formulation also comprises stabilizing agent consisting of shellac and its constituent aliphatic polyhydroxy acids, ascorbic acid, benzoic acid or fumaric acid, preferably saturated polyglycolized glyceride containing 8-18C saturated fatty acids; and pharmaceutically acceptable excipient consisting of sucrose, silicone dioxide, silicified microcrystalline cellulose, fatty acids, fatty acid salts, fatty acid esters, and/or talc. IT also comprises film coat. The acrylic acid polymer is a copolymer of acrylic acid. The pharmaceutically acceptable excipient is a metallic salt of stearate comprising aluminum, calcium, magnesium, sodium, or zinc.
 Preferred Composition: The saturated polyglycolized glyceride is present at 1-75 wt.%. The formulation also comprises 20-25 wt.% uncrosslinked polymer; 1-75 wt.% stabilizing agent; less than 10 wt.% talc; and less than 10 wt.% magnesium stearate. It comprises (wt.%) bupropion hydrochloride (39), hydroxyethylcellulose (25), saturated polyglycolized

glyceride (30), talc (5), and magnesium stearate (1); or bupropion hydrochloride (39), sodium carboxymethyl cellulose (20), saturated polyglycolized glyceride (25), lactose (10), talc (5), and magnesium stearate (1). The formulation comprises 5-10 wt.% crosslinked insoluble polymer, 20-75 preferably 20-30 wt.% saturated polyglycolized glyceride, and 39 wt.% bupropion hydrochloride.

L88 ANSWER 3 OF 3 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2004-021488 [02] WPIX

DNC C2004-006865

TI Composition useful for reducing iron deficiency in a pregnant or lactating female comprises iron in a form of an iron amino acid chelate or its salt.

DC B05 D13

IN BYDLON, R J; DEMPSEY, M; ERBSKORN, A; HURD, W R; NIDAMARTY, P; WILLIAMS, W C; HURD, W A

PA (INTE-N) INTEGRITY PHARM CORP

CYC 103

PI US--2003206969 A1 20031106 (200402)* 12 A61K-031-555

WO--2003092674 A1 20031113 (200402) EN A61K-031-295

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS

LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK

DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR

KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL

PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA

ZM ZW

AU--2003231249 A1 20031117 (200442) A61K-031-295

ADT US--2003206969 A1 Provisional 2002US-377339P 20020502, 2003US-0375600 20030227; WO--2003092674 A1 2003WO-US13663 20030501; AU--2003231249 A1 2003AU-0231249 20030501

FDT AU--2003231249 A1 Based on WO--2003092674

PRAI 2002US-377339P 20020502; 2003US-0375600 20030227

IC ICM A61K-031-295; A61K-031-555

ICS A23L-001-302; A23L-001-304; A61K-033-26

AB US2003206969 A UPAB: 20040107

NOVELTY - A composition (C1) comprises iron in a form of an iron amino acid chelate (A) or its salt. (C1) is in a single dosage formulation.

ACTIVITY - Antianemic.

MECHANISM OF ACTION - None given.

USE - For reducing iron deficiency in a pregnant or lactating female suffering from anemia (claimed).

ADVANTAGE - The single dosage formulation comprises enteric coating for providing delayed release of ingredients in the supplement administered to the mammal by reducing or minimizing degradation and clearance of the composition prior to absorption and for providing enhanced absorption. The composition provides increased bioavailability of the iron into the blood, thus provides greater efficiency in supplementing iron in a diet while avoiding deleterious side effects in the gastrointestinal tract.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B05-A01B; B05-A03A; B06-D09; B14-F03; D03-H01T2

ABEX UPTX: 20040107

SPECIFIC COMPOUNDS - Ferrous bis-glycinate chelate is specifically claimed as the iron-amino acid chelate.

ADMINISTRATION - The single dosage formulation is in the form of pill, tablet (preferably chewable tablet), caplet or capsule. The supplement of the iron is provided in a once-a-day dose (claimed). The composition is administered orally in a dosage of 0.01 - 5 mg.

EXAMPLE - A multivitamin/multimineral supplement comprised:

vitamin A (3000 IU), vitamin D (400 IU), vitamin E (30 mg), vitamin C (120 mg), folic acid (1 mg), vitamin B1 (1.8 mg), vitamin B2 (4 mg), niacinamide (20 mg), vitamin B6 (25 mg), vitamin B12 (12 mcg),

calcium (100 mg), copper (2 mg), iron (29 mg), zinc (25 mg) and magnesium (25 mg).

TECH UPTX: 20040107

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Composition: The composition further comprises a non-iron mineral or its salt, vitamin or its salt, and folic acid (0.01 - 5 mg). Preferred Components: The amino acid is alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamine, glutamic acid, glycine, histidine, hydroxyproline, isoleucine, lysine, leucine, methionine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and/or valine. The iron-amino acid chelate (25, preferably 75, especially 90) wt.% is ferrous bis-glycinate chelate (10 - 200 mg). The salt form of iron (25 - 75 wt.%) is ferrous fumarate (10 - 200 mg), ferrous sulfate, ferrous succinate, ferrous gluconate, ferrous lactate, ferrous tartarate and/or ferrous citrate (preferably ferrous fumarate). The mineral is calcium, copper, zinc and/or magnesium. The iron has a total weight of 5 - 200 mg.

=> d his

(FILE 'HOME' ENTERED AT 08:18:18 ON 24 JAN 2006)

FILE 'HCAPLUS' ENTERED AT 08:18:40 ON 24 JAN 2006

L1 1 US2005142124/PN OR US2003-750545#/AP,PRN
E KAISER J/AU
L2 115 E3
E KAISER JON/AU
L3 3 E3-4
E INTERGRAT/CS,PA
E INTEGRATIVE/CS,PA
E INTEGRATIVE HEALTH/CS,PA
E INTEGRATIVE HEALTH/CS,PA
L4 1 E5-8

FILE 'REGISTRY' ENTERED AT 08:22:37 ON 24 JAN 2006

FILE 'HCAPLUS' ENTERED AT 08:22:37 ON 24 JAN 2006

L5 TRA L1 1- RN : 40 TERMS

FILE 'REGISTRY' ENTERED AT 08:22:38 ON 24 JAN 2006

L6 40 SEA L5

FILE 'WPIX' ENTERED AT 08:22:41 ON 24 JAN 2006

L7 1 L1
E KAISER K/AU
E KAISER J/AU
L8 144 E3,E7
E INTEGRATIVE HEALTH/CS,PA
L9 1 E5-6
L10 20599 INTE/PACO OR INTE-N/PACO

FILE 'REGISTRY' ENTERED AT 11:24:23 ON 24 JAN 2006

L11 2 L6 AND BETAIN?

FILE 'WPIX' ENTERED AT 11:36:14 ON 24 JAN 2006

L12 7810 B03-F/MC OR V330/M0,M1,M2,M3,M4,M5,M6 OR (A61K031-375 OR C07D30
E VITAMIN C/CN
L13 3 E3-4
E ASCORBIC ACID/CN
L14 11 E3-7,E20,E24-27,E30,E45-47
L15 13 L13-14
SEL DCSE
EDIT /DCSE /DCRE
L16 4113 E1-13/DCRE
SEL SDCN L15

L17 EDIT /SDCN /DCN
 L18 6735 E14-27/DCN
 9450 0035/DRN
 SEL SDRN L15
 EDIT /SDRN /DRN
 L19 9450 E28/DRN
 L20 12757 L12,L16-19
 L21 6591 (B03-H OR C03-H)/MC OR V350/M0,M1,M2,M3,M4,M5,M6 OR C07D311-72/
 E VITMAIN E/CN
 E VITAMIN E/CN
 L22 6 E3-4,E6-8
 E TOCOPHEROL/CN
 L23 50 E3-65,E69-76,E81-95
 L24 52 L22-23
 SEL DCSE
 EDIT /DCSE /DCRE
 L25 3604 E1-52/DCRE
 SEL SDCN L24
 EDIT /SDCN /DCN
 L26 5526 E53-108/DCN
 SEL SDRN L24
 EDIT /SDRN /DRN
 L27 5208 E109-112/DRN
 L28 5665 TOCOPHEROL
 L29 8848 L21,L25-27
 L30 6648 (B03-H OR C03-H)/MC OR V323/M0,M1,M2,M3,M4,M5,M6 OR C07D213-67/
 E PYRIDOXINE/CN
 L31 17 E3-34
 SEL DCSE
 EDIT /DCSE /DCRE
 L32 1015 E1-17/DCRE
 SEL SDCN L31
 EDIT /SDCN /DCN
 L33 1535 E18-35/DCN
 L34 1798 0252/DRN
 L35 1386 PYRIDOXINE
 L36 8061 L30,L32-35
 L37 6050 (B03-A OR C03-A)/MC OR V310/M0,M1,M2,M3,M4,M5,M6
 L38 1925 (C07C403 OR A61K031-07)/IPC
 E VITAMIN A/CN
 L39 9 E3-10
 SEL DCSE
 EDIT /DCSE /DCRE
 L40 1904 E1-9/DCRE
 SEL SDCN L39
 EDIT /SDCN /DCN
 L41 2942 E10-20/DCN
 SEL SDRN L39
 EDIT /SDRN /DRN
 L42 3443 E21-25/DRN
 E VITAMIN A/CN
 E BETACAROTENE/CN
 L43 2 E3-4
 E BETA CAROTENE/CN
 SEL DCSE
 EDIT /DCSE /DCRE
 L44 1893 E1-2/DCRE
 SEL SDCN L43
 EDIT /SDCN /DCN
 L45 3010 E3-4/DCN
 L46 3729 (0282 OR 1662)/DRN
 L47 8464 L37-38,L40-42,L44-46
 L48 5337 VITAMIN (1W)A# OR BETACAROTEN? OR BETA (1W)CAROTENE?
 L49 10587 L47-48
 L50 6400 E31-G/MC OR B134/M0,M1,M2,M3,M4,M5,M6 OR C01B019/IPC
 E SELENIUM/CN

L51 29 E3-31,E33-38
 SEL DCSE L51
 EDIT /DCSE /DCRE
 L52 1250 E1-29/DCRE
 SEL SDCN L51
 EDIT /SDCN /DCN
 L53 1795 E30-57/DCN
 SEL SDRN L51
 EDIT /SDRN /DRN
 L54 2250 E58-60/DRN
 L55 7112 L50,L52-54
 L56 52859 E35-C/MC OR A430/M0,M1,M2,M3,M4,M5,M6 OR (A61K007-36 OR A61K031
 E ZINC/CN
 L57 10 E3-8
 SEL DCSE
 EDIT /DCSE /DCRE
 L58 5799 E1-10/DCRE
 SEL SDCN L57
 EDIT /SDCN /DCN
 L59 10098 E11-22/DCN
 SEL SDRN L57
 EDIT /SDRN /DRN
 L60 24518 E23-25/DRN
 L61 66871 L56,L58-60
 L62 226 C07D339-04/IPC
 E ALPHA LIPOIC/CN
 E ALPHA-LIPOIC/CN
 L63 1 E4,E6
 SEL DCSE
 EDIT /DCSE /DCRE
 L64 530 E1/DCRE
 SEL SDCN L63
 EDIT /SDCN /DCN
 L65 637 E2/DCN
 L66 878 LIPOIC (1W)ACID
 L67 1138 L62,L64-66
 E CARNITINE/CN
 E ACETYL-L-CARN/CN
 L68 11 E4-14
 SEL DCSE
 EDIT /DCSE /DCRE
 L69 97 E1-11/DCRE
 SEL SDCN L68
 EDIT /SDCN /DCN
 L70 114 E12-23/DCN
 L71 1222 L67,L69-70
 E N-ACETYL-CYST/CN
 L72 1 E4
 SEL DCSE
 EDIT /DCSE /DCRE
 L73 511 E1/DCRE
 EDIT /SDCN
 SEL SDCN L72
 EDIT /SDCN /DCN
 L74 714 E2/DCN
 L75 978 N (1W)ACETYLCYSTEIN? OR N (1W)ACETYL(1W)CYSTEIN?
 L76 1188 L73-75
 E COENZYME Q10/CN
 L77 2 E3,E6
 SEL DCSE L77
 EDIT /DCSE /DCRE
 L78 482 E1-2/DCRE
 SEL SDCN L77
 EDIT /SDCN /DCN
 L79 610 E3-4/DCN
 E CO ENZYME/CN

L80 E CO-ENZYME/CN
762 COENZYME (1W) (10 OR Q10 OR Q 10)
L81 976 L78-80
E GLUTATHIONE/CN
L82 2 E3,E16
SEL DCSE
EDIT /DCSE /DCRE
L83 678 E1-2/DCRE
SEL SDRN L82
EDIT /SDCN
DEL SEL Y
SEL SDCN L82
EDIT /SDCN /DCN
L84 1043 E1-2/DCN
L85 3973 GLUTATHIONE
L86 4126 L83-85
L87 2506 L20,L29,L39,L49 AND L61,L55
L88 3 L87 AND L7-10
L89 455287 L87 AND (B12-C09 OR C12-C09 OR B14-S09 OR C14-S09)/MC OR (P86?
L90 2144 L87 AND L89
L91 153 L90 AND L67
L92 153 L91 AND L71
L93 51 L91 AND L76
L94 57 L91 AND L81
L95 60 L91 AND L86
L96 90 L92-93 AND L81,L86
L97 29 L96 NOT (PY>2003 OR AY>2003 OR PRY>2003)
SEL AN 1 10 15 17 19 22 24
L98 7 E3-9 AND L97

=>